4 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Untitled document
    4
    1. karim2001khoury 19 Feb 2026
      Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer

      [Paper-level Aggregated] PMCID: PMC4378307

      Evidence Type(s): Prognostic, Oncogenic

      Justification: Prognostic: The text indicates that KRAS mutations, specifically G12D and G12S, are associated with poor prognosis in progression-free survival (PFS), demonstrating their role as independent negative prognostic factors. Oncogenic: The presence of KRAS mutations, including G12D and G12S, is indicative of oncogenic activity, as they are associated with worse clinical outcomes in patients.

      Gene→Variant (gene-first): KRAS(3845):G12D KRAS(3845):G12S

      Genes: KRAS(3845)

      Variants: G12D G12S

      CIViC paper-level aggregated PMC4378307
    2. karim2001khoury 19 Feb 2026
      The Kaplan-Meier survival analysis of individual subtypes of KRAS mutation performed in this study showed the following results: the G12D subtype was associated with poor prognosis in PFS (log-rank p = 0.02), other subty

      [Paragraph-level] PMCID: PMC4378307 Section: RESULTS PassageIndex: 7

      Evidence Type(s): Prognostic

      Justification: Prognostic: The passage indicates that the G12D and G12S subtypes of KRAS mutations are associated with poor prognosis in progression-free survival (PFS) and overall survival (OS), respectively, which correlates with disease outcomes independent of therapy.

      Gene→Variant (gene-first): 3845:G12D 3845:G12S

      Genes: 3845

      Variants: G12D G12S

      CIViC paragraph-level PMC4378307 Prognostic
    3. karim2001khoury 19 Feb 2026
      Results: Among a total of 148 patients, 48 (32%) had mutated KRAS, 77% at codon 12 and 23% at codon 13. The PFS was significantly worse in the mutant KRAS patients in comparison to wild type KRAS patients (p < 0.05). The

      [Paragraph-level] PMCID: PMC4378307 Section: ABSTRACT PassageIndex: 3

      Evidence Type(s): Prognostic, Diagnostic

      Justification: Prognostic: The passage indicates that KRAS mutation, specifically G12D, is associated with a poor prognosis in progression-free survival (PFS), demonstrating its role as an independent negative prognostic factor. Diagnostic: The mention of KRAS mutations, including G12D, being associated with specific outcomes in patients suggests that these mutations can be used to classify or define disease subtypes.

      Gene→Variant (gene-first): 3845:G12D

      Genes: 3845

      Variants: G12D

      CIViC paragraph-level PMC4378307 Prognostic Diagnostic
    4. karim2001khoury 19 Feb 2026
      Results: Among a total of 148 patients, 48 (32%) had mutated KRAS, 77% at codon 12 and 23% at codon 13. The PFS was significantly worse in the mutant KRAS patients in comparison to wild type KRAS patients (p < 0.05). The

      [Paragraph-level] PMCID: PMC4378307 Section: ABSTRACT PassageIndex: 3

      Evidence Type(s): Prognostic, Diagnostic

      Justification: Prognostic: The passage indicates that KRAS mutation, specifically G12D, is associated with a poor prognosis in progression-free survival (PFS), demonstrating its role as an independent negative prognostic factor. Diagnostic: The mention of KRAS mutations, including G12D, being associated with specific outcomes in patients suggests that these mutations can be used to classify or define disease subtypes.

      Gene→Variant (gene-first): 3845:G12D

      Genes: 3845

      Variants: G12D

      CIViC paragraph-level PMC4378307 Prognostic Diagnostic
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC4378307/pdf/fgene-06-00116.pdf